1. Home
  2. WD vs ADPT Comparison

WD vs ADPT Comparison

Compare WD & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Walker & Dunlop Inc

WD

Walker & Dunlop Inc

HOLD

Current Price

$63.63

Market Cap

2.1B

Sector

Finance

ML Signal

HOLD

Logo Adaptive Biotechnologies Corporation

ADPT

Adaptive Biotechnologies Corporation

HOLD

Current Price

$17.14

Market Cap

2.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WD
ADPT
Founded
1937
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
2.5B
IPO Year
2010
2019

Fundamental Metrics

Financial Performance
Metric
WD
ADPT
Price
$63.63
$17.14
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
10
Target Price
$83.33
$16.60
AVG Volume (30 Days)
257.9K
2.1M
Earning Date
02-12-2026
02-10-2026
Dividend Yield
4.10%
N/A
EPS Growth
20.18
N/A
EPS
3.37
N/A
Revenue
$1,160,070,000.00
$252,754,000.00
Revenue This Year
$21.20
$50.86
Revenue Next Year
$10.20
$0.53
P/E Ratio
$19.41
N/A
Revenue Growth
17.65
42.57
52 Week Low
$58.60
$6.26
52 Week High
$97.70
$20.76

Technical Indicators

Market Signals
Indicator
WD
ADPT
Relative Strength Index (RSI) 51.39 53.83
Support Level $62.56 $15.45
Resistance Level $66.47 $18.39
Average True Range (ATR) 1.68 0.87
MACD 0.67 0.11
Stochastic Oscillator 63.91 61.91

Price Performance

Historical Comparison
WD
ADPT

About WD Walker & Dunlop Inc

Walker & Dunlop Inc is a United States-based commercial real estate finance company. It is principally engaged in originating, selling, and servicing a number of multifamily and other commercial real estate financing products that are sold under the programs of Freddie Mac, Fannie Mae, Ginnie Mae, and the Federal Housing Administration. The company is managed based on three reportable segments: Capital Markets (CM), Servicing & Asset Management (SAM), and Corporate. The company generates a majority of total revenue from gains from mortgage banking activities and servicing fees. It conducts business solely in the United States.

About ADPT Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).

Share on Social Networks: